Comparison Between Effect of Systemic Fentanyl Infusion and Fentanyl Added As an Adjuvant to Lidocaine in Bier Block for Controlling Pain in Patients Undergoing Hand Surgeries

Injury and deformity of the upper extremity can result in dysfunction to nerves, tendons and bones which can lead to disability and pain.
Various techniques of regional anesthesia are frequently used for upper extremity surgery. Specifically, intravenous regional anesthesia, the Bier block, is an effective anesthetic technique. This technique, developed by Dr August Bier in 1908, provides complete anesthesia, a bloodless field, and eliminates the need for general anesthesia. However, it was not until the 1960s that this technique was reintroduced and used in upper extremity surgery due to several disadvantages and reports of major complications. Because of the dose of lidocaine and tourniquet time, there is potential for cardiac and neurological complications such as arrhythmias, seizures, and compartment syndrome the aim of this study To evaluate the effect of Systemic Fentanyl Infusion compared to addition of Fentanyl as An Adjuvant to Lidocaine in Bier Block for Controlling Pain in Patients Undergoing Hand Surgeries

Start Date01 Dec 2024

Sponsor / Collaborator

Assiut University

NCT06094946 / Not yet recruitingNot ApplicableIIT

Parturient Satisfaction With Epidural Analgesia During Parturient Controlled Pump

Those prospective parturients that express that they may want an epidural labour analgesia for their delivery will be informed about the possibility to choose between a pump driven epidural or midwife administered intermittent boluses.

Start Date01 Dec 2024

Sponsor / Collaborator

Helsinki University Central Hospital

CTRI/2024/11/076851 / Not yet recruitingPhase 4IIT

Comparison of the effect of intrathecal fentanyl citrate and magnesium sulphate as adjuvants to hyperbaric levobupivacaine 0.5 per cent for spinal anaesthesia in patients undergoing lower limb orthopaedic surgeries A prospective randomised study - Nil

Start Date30 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Fentanyl Citrate

100 Translational Medicine associated with Fentanyl Citrate

100 Patents (Medical) associated with Fentanyl Citrate

483

Literatures (Medical) associated with Fentanyl Citrate

06 Nov 2024·Cureus Journal of Medical Science

Effective Pain Management of Postherpetic Neuralgia Using a Combination of Analgesics and Conservative Measures

Article

Author: Hirono, Yasuo ; Fukumoto, Shintaro ; Iino, Shiro ; Kodama, Maiko ; Takano, Chihaya ; Kitano, Yuhei ; Tsubaki, Takayoshi ; Kodaka, Erina

Postherpetic neuralgia (PHN) is characterized by persistent pain following the resolution of a herpes zoster rash. PHN is often resistant to treatment and can significantly reduce the patient's quality of life. Effective symptom relief is crucial and various treatments, including pharmacotherapy, have been attempted. Given that symptoms can persist for a prolonged period, they can substantially affect the physical and mental well-being of the patients. A 73-year-old man developed herpes zoster while undergoing treatment for a head angiosarcoma. Despite the resolution of the rash, the pain persisted, leading to the diagnosis of PHN. Treatment was initiated with a range of medications, including mecobalamin, pregabalin, and a combination of tramadol and acetaminophen, along with general pain relievers standardized as WHO Step 1 medications, which include acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs). However, achieving adequate pain control is challenging and results in frequent hospitalizations. Due to the patient's depression and the concurrent use of a selective serotonin reuptake inhibitor, duloxetine hydrochloride could not be prescribed. Instead, opioid therapy with continuous fentanyl citrate infusion was initiated. Eventually, the treatment was switched to oxycodone hydrochloride, which successfully stabilized the patient's symptoms. The use of conservative measures such as hot compresses also contributes to symptom relief. Alleviating pain symptoms using a combination of pharmacotherapeutic and non-pharmacological treatments is extremely important.

22 Jul 2023·BMC anesthesiology

Effect of nalbuphine plus ropivacaine on vaginal labor in epidural analgesia.

Article

Author: Cao, Xiao-Sheng ; Pang, Zhao ; Wen, Xue-Jin ; Ou, Lian-Chun ; Yin, Biao ; Liu, Li-Wen ; Liu, Guo-Hua ; He, Quan-Yan

BACKGROUND:

Various approaches using epidural analgesia have been employed for relieving labor pain and promoting spontaneous delivery. We aimed to evaluate the effect of nalbuphine and ropivacaine versus fentanyl and ropivacaine on the duration of delivery in parturients.

METHODS:

Clinical data of 160 full-term primiparous women who received either nalbuphine or fentanyl in combination with ropivacaine infusion for epidural labor analgesia in our hospital from December 2020 to May 2022 were retrospectively analyzed. The participants were divided into two groups based on anesthesia methods: nalbuphine group (NR group, n = 78) received 0.2 mg/mL nalbuphine combined with 0.1% ropivacaine hydrochloride for patient-controlled epidural analgesia (PCEA) and fentanyl group (FR group, n = 82) received 2 ug/mL fentanyl citrate and 0.1% ropivacaine hydrochloride for PCEA. Both groups received an epidural blockade for labor analgesia at lumbar 2-3 interspace. The duration of the first, second, and third stages of labor, the onset of analgesia, and time before delivery (T0), 15 min of analgesia (T1), 30 min of analgesia (T2), full opening of the uterine opening (T3),exerts force during childbirth(T4), heart rate (HR), blood pressure (BP), blood saturation (SpO2), visual analogue pain scale (VAS) score, Ramsay sedation score, and modified Bromage score, and 5 min were recorded at 2 h postpartum (T5). The neonatal Apgar score, neonatal behavioral neurological assessment (NBNA) score, maternal nausea, vomiting, and itchy skin were recorded.

RESULTS:

Compared with the FR group, the first stage of labor duration (p < 0.05) and total duration of labor (p < 0.05) were shortened and the onset of analgesia (p < 0.05) was increased in the NR group. NR group had lower incidence of urinary retention than FR group (p < 0.05). The maternal and neonatal investigational parameters and scores had no significant difference between the two groups.

CONCLUSIONS:

Nalbuphine combined with ropivacaine in epidural block labor has a faster onset of analgesia and has a lower incidence of urinary retention than fentanyl combined with ropivacaine, and nalbuphine shortens the duration of the first and total stages of labor. Both nalbuphine and fentanyl can reduce pain during labor, have little effect on maternal hemodynamics, and have no significant effect on neonatal Apgar or NBNA scores.

01 May 2023·Applied spectroscopy

Quantitative Raman Cross-Sections and Band Assignments for Fentanyl and Fentanyl Analogs

Article

Author: Kline, Neal D. ; Wilcox, Phillip G. ; Pardoe, Ian J. ; Emmons, Erik D. ; Guicheteau, Jason A.

Raman cross sections and spectra were measured for five synthetic opioid fentanyl analogs: fentanyl citrate, sufentanil citrate, alfentanil HCl, carfentanil oxalate, and remifentanil HCl. The measurements were performed with excitation wavelengths in the visible (532 nm) and near infrared (785 nm). In addition, density functional theory (DFT) calculations were employed to generate simulated spectra of the compounds and aid in identification of the observed spectral modes. These cross-section measurements and calculations were also used to assess results from a series of measurements of fentanyls cut with other powdered materials. These measurements are valuable for assessment of field-deployable Raman chemical sensors for detection of fentanyl and fentanyl analogs, including when mixed with other materials.

News (Medical) associated with Fentanyl Citrate

24 Oct 2024

·orexo.com

Orexo Interim Report Q3 2024

Q3 2024 highlights › Total net revenues of SEK 136.5 m (156.1) › EBITDA of SEK -0.7 m (-9.5) › Net earnings of SEK -41.9 m (-33.3) › US Commercial segment net revenues of SEK 131.0 m (140.4), in local currency USD 12.6 m (13.0) › Cash flow from operating activities of SEK -13.4 m (-21.9), cash and cash equivalents of SEK 114.9 m (184.2) › Earnings per share before and after dilution amounted to SEK -1.21 (-0.97) › Orexo AB´s sustainability work ranked among the top five percent of all 70,000 businesses worldwide reviewed by EcoVadis › For OX124, our high dose naloxone rescue medication for opioid overdose, a complete response letter was received from the FDA requesting additional technical data on the final commercial product as well as further information from a new human factors study (HF study). A new HF study was successfully conducted in July. › The financial guidance for 2024 reiterated. Important events after the end of the period › An exploratory phase 1 clinical study was initiated for OX640 in participants with allergic rhinitis. A quarter of setbacks and achievements CEO Comments in brief The third quarter has been challenging, starting with the delay of OX124’s approval and, from a financial perspective, we had a marginally negative EBITDA. This negative EBITDA result was primarily due to higher legal costs, retrospective adjustments of the Abstral® royalties and lower Zubsolv® sales. The development was partly compensated by a 15 percent drop in expenses. Zubsolv prescription volumes in the US are stable, but sales were negatively impacted by a reduction in inventory levels at wholesalers and a weakening USD. Looking beyond the third quarter, I am pleased to see Zubsolv sales continuing to show stable demand and growth in some segments. We remain optimistic that we can get OX124, our high dose rescue medication for opioid overdose, approved and expand treatment alternatives for patients suffering from opioid use disorder. In the quarter we made progress in our business development efforts, attracting new companies to leverage our AmorphOX® technology, and we continue to see interest in OX640. Also, there are signs that we are making some progress to resolve the legal disputes in the US. Nikolaj Sørensen President and CEO For the full CEO comments view PDF Contact persons quarterly report Nikolaj Sørensen, President and CEO Fredrik Järrsten, EVP and CFO Lena Wange, IR & Communications Director Tel: +46 18 780 88 00, +1 855 982 7658, E-mail: ir@orexo.com. Presentation On October 24, at 2 pm CET analysts, investors and media are invited to attend a presentation, incl. a Q&A. To attend via teleconference where you can ask questions verbally: https://conference.financialhearings.com/teleconference/?id=50048738 When registered you will be provided phone numbers and a conference ID to access the conference. To attend via webcast: https://ir.financialhearings.com/orexo-q3-report-2024 Prior to the call, presentation material will be available on the website under Investors/ Report Archive This information is information that Orexo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-24 08:00 CEST. Attachments Orexo Q3 2024 Interim Report

Phase 1Financial Statement

20 Sep 2024

·www.drugs.com

FDA Says Drug Makers Will Stop Producing Fentanyl 'Lollipops'

FRIDAY, Sept. 20, 2024 -- Controversial fentanyl lollipops and similar products will no longer be made by drug makers, the U.S. Food and Drug Administration has announced. Known as TIRF medications, these products contain fentanyl and are used to manage breakthrough pain in cancer patients who have become tolerant to around-the-clock opioid therapy, the FDA said in a statement released this week. The decision by drug makers to stop selling such medicines follows decades of investigations and lawsuits against the drugmakers that had marketed the fast-acting painkillers too aggressively, CBS News reported. In 2020, the FDA first tightened prescribing restrictions on the products, in response to data suggesting they were being given to patients who are not opioid-tolerant. Drugmaker Cephalon had the FDA's approval to market these drugs for years under brand names like Actiq , a sweetened lozenge on a stick, or Fentora , a tablet that dissolves in the mouth. Generic pharmaceutical manufacturer Teva Pharmaceuticals acquired Cephalon in 2011, when the market for Actiq was worth around $173 million a year, CBS News reported. Teva officials did not respond Thursday to a request for comment on why it will stop selling the products, CBS News reported. In 2022, Teva settled lawsuits from state and local governments that had accused the company of promoting Actiq and other powerful fentanyl painkillers for patients without cancer and downplaying addiction risks. Teva will stop selling the products on Sept. 30, the FDA said. "FDA did not request this discontinuation. It is important to note that FDA does not manufacture medicine and cannot require a pharmaceutical company to make a medicine, make more of a medicine or change the distribution of a medicine," the agency added. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AcquisitionDrug ApprovalPriority Review

13 Dec 2023

·www.globenewswire.com

TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. “I am pleased to welcome Thomas King to our Board of Directors,” said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. “Tom is an exceptionally accomplished executive who has held leadership positions at life sciences companies over the last three decades. In addition, his extensive board experience will provide us with valuable insights and perspectives as we seek to advance our two lead candidates, TFF VORI and TFF TAC, into later-stage clinical testing.” “I am very excited to join the Board of TFF Pharmaceuticals at a time when the Company is demonstrating how its ground-breaking Thin Film Freezing technology can be applied in the clinic to address the significant unmet need in patients with rare diseases,” said Mr. King. “I look forward to working alongside Harlan and our fellow Board members to help advance the company’s mission of significantly improving new and existing therapies for the benefit of patients.” Mr. King has over 30 years of executive leadership and board experience in the life sciences industry. Presently, Mr. King sits on the board of several companies, including Achieve Life Sciences (Nasdaq: ACHV), Kinaset Therapeutics, and Concentric Analgesics. From 2003 to 2016, Mr. King served as the President, Chief Executive Officer and Director of Alexza Pharmaceuticals, where he led multiple stock offerings and debt transactions from 2003 through 2015 (IPO in 2006), raising in excess of $600mm and ultimately leading to the successful M&A transaction with Grupo Ferrer. Prior to joining Alexza, he was the President, Chief Executive Officer and Director of Cognetix, Inc. From 1994 to 2000, Mr. King served in multiple executive roles and as a Director with Anesta Corp., where he led two successful follow-on stock offerings, NDA and MAA approvals for oral transmucosal fentanyl citrate (Actiq®), and a successful M&A transaction with Cephalon in 2000. Earlier in his career, Mr. King served as Vice President of Marketing and Business Development with Somatogen, Inc., and before joining Somatogen, he served as Director of the Cardiovascular Business Unit at Abbott Laboratories, Pharma Products Division. Mr. King received his B.A. degree in chemistry from McPherson College and an MBA from the University of Kansas Graduate School of Business. ABOUT TFF PHARMACEUTICALS’ THIN FILM FREEZING (TFF) TECHNOLOGY TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The TFF process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by TFF can deliver as much as 75% of the dose to the deep lung. TFF does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of TFF can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products. ABOUT TFF PHARMACEUTICALS TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile TFF technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF VORI (Voriconazole Inhalation Powder) and TFF TAC (Tacrolimus Inhalation Powder). The Company continues collaborations with a broad array of pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by over 170 patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com. SAFE HARBOR This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including, plans for releasing initial clinical data by the end of 2023 and the benefits of the Company’s TFF platform. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to release initial clinical data for TFF VORI and TFF TAC by the end of 2023 or, if it is able to do so, that such clinical data will be positive, (ii) the risk that the Company’s preclinical and IND enabling studies of the dry powder formulation of the universal influenza vaccine may not be successful, (iii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iv) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, and (iv) those other risks disclosed in the section “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2023. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. Investor Relations Contact:Corey Davis, Ph.D. LifeSci Advisors (212) 915-2577cdavis@lifesciadvisors.com Source: TFF Pharmaceuticals, Inc.

Executive ChangeVaccineIPO

100 Deals associated with Fentanyl Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D01399	Fentanyl Citrate	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	US	Adalvo Ltd.	16 Jul 2009
Breakthrough Pain	EU	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	IS	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	LI	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	NO	Teva Pharmaceuticals Europe BV	04 Apr 2008
Cancer Pain	US	Cephalon, Inc.	04 Nov 1998
Hyperemesis Gravidarum	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Anesthesia	US	Rising Pharmaceuticals, Inc.Startup	19 Feb 1968

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 3	IT	L. Molteni & C. dei F.lli Alitti Società di Esercizio SpA	01 Sep 2014
Low Back Pain	Phase 3	US	Cephalon, Inc.	01 Sep 2005
Neuralgia	Phase 3	US	Cephalon, Inc.	01 Sep 2005
Neoplasms	Phase 3	US	Cephalon, Inc.	01 Apr 2004
Anemia, Sickle Cell	Phase 2	US	Cephalon, Inc.	01 Oct 2006
Anemia, Sickle Cell	Phase 2	CA	Cephalon, Inc.	01 Oct 2006
Anemia, Sickle Cell	Phase 2	PR	Cephalon, Inc.	01 Oct 2006
Burns	Phase 2	US	Cephalon, Inc.	01 Oct 2006
Burns	Phase 2	CA	Cephalon, Inc.	01 Oct 2006
Burns	Phase 2	PR	Cephalon, Inc.	01 Oct 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02531971 (CTgov)	Phase 4	-	24	Duragesic (Duragesic)	kzgtlezndw(fpyvzjclkr) = khuimzmzia wjvmnrmdbw (pecpwsffsd, ilpicnbvqn - yeuddwkwtd)	-	26 Mar 2020
NCT02531971 (CTgov)	Phase 4	-	24	fentanyl (Mylan)	kzgtlezndw(fpyvzjclkr) = tdzngrnnhw wjvmnrmdbw (pecpwsffsd, lcsnarzhjw - kscunbfyzc)	-	26 Mar 2020
NCT01516684 (CTgov)	Phase 2	Neoplasms	33	EMLA cream (Arm A (EMLA))	suqefckwla(njymhsaxgg) = gabnzomczs miridrwwbn (hcfawcltls, ivytqtbodu - orpyvlixmu) View more	-	06 Sep 2019
NCT01516684 (CTgov)	Phase 2	Neoplasms	33	Placebo (Arm B (Placebo))	suqefckwla(njymhsaxgg) = fsedovrjoo miridrwwbn (hcfawcltls, thxdxoxwww - idhigyoudf) View more	-	06 Sep 2019
NCT03071744 (CTgov)	Phase 2	Bone metastases	6	Lazanda	sixruitahp(mfwpyacjwz) = qltwutctkf sklmjskvox (ebpefzjerj, uxrrnmidbv - pazwkpslib) View more	-	23 Jul 2019
NCT00696137 (CTgov)	Phase 3	Cancer Pain \| Respiratory Insufficiency	5	BEMA Fentanyl	wmhagllebs(rqxpqypuoe) = ipagzwurli kinypnyjgn (surolgpeuw, aswnfztszr - jrbvvqhesl) View more	-	19 Dec 2018
NCT02571634 (RFA, CTgov)	Phase 4	Pain, Procedural	23	Lazanda	njloduxwrm(qjyvrlurhu) = yfdtlwuuar dfewgyqoyp (fpuyqmtwzt, vvqcrhluuu - mkzixhqffm) View more	-	25 Oct 2016
NCT01482091 (CTgov)	Phase 4	Vaso-occlusive crisis \| Pain \| Anemia, Sickle Cell	124	Normal Saline (Intranasal Saline)	ftwytoqpkw(yxxnapseaz) = sztekspeec iqvadoefnc (zuaznryfjy, jvlddqalgc - sbdlzbosdj) View more	-	19 Aug 2016
NCT01482091 (CTgov)	Phase 4	Vaso-occlusive crisis \| Pain \| Anemia, Sickle Cell	124	Fentanyl Citrate (Intranasal Fentnayl)	ftwytoqpkw(yxxnapseaz) = uktzwovekf iqvadoefnc (zuaznryfjy, tnthkktqam - jaiodbeoos) View more	-	19 Aug 2016
NCT00387010 (CTgov)	Phase 3	Breakthrough Pain \| Anxiety Disorders \| Chronic Pain	218	Fentanyl Buccal Tablets	snotbmqgil(sojuvvjbny) = ggcfvmyqic itsxqdwmup (otjtddkuhb, fthtnxosjj - tbjvrkyziz) View more	-	22 Oct 2012
NCT00293020 (CTgov)	Phase 3	Breakthrough Pain \| Neoplasms	244	Fentanyl	rjfgfeflml(tohamuhutg) = ruljhjpsry kqmynbehvr (cjspzdqovr, zomrlhlvdg - qmftrcytjw) View more	-	05 Oct 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis